A Heart Disease Cure for Pericarditis? Phase 3 Trial Advances | David Elsley - Cardiol Therapeutics

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL) as CEO David Elsley reveals the enrollment of their first patient in the pivotal Phase 3 MAVERICK trial for recurrent pericarditis. In this concise interview, Elsley discusses how their oral drug therapy aims to prevent new episodes of this debilitating heart condition, the impressive Phase 2 results showing significant pain reduction, and the potential timeline for market entry by mid-2026. With trial sites at prestigious institutions like Mass General, Cleveland Clinic, and Mayo Clinic, and a market potential approaching $1 billion by 2028, investors won't want to miss this significant development in cardiovascular medicine. Watch now to learn about this promising treatment for the 40,000 Americans suffering from recurrent pericarditis, and don't forget to like, comment, and subscribe for more biotech investment insights!
#biotechnology #cardio #stocks #nasdaq #investing #smallcapstocks

Catch our full suite of content below:
Website: https://thedeepdive.ca/
Twitter: https://twitter.com/TheDeepDive_ca
Facebook: https://www.facebook.com/TheDeepDive.ca/
Instagram: https://www.instagram.com/the.deep.dive/
LinkedIn: https://www.linkedin.com/company/the-...

FULL DISCLOSURE:
Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

0:00 - Introduction
0:42 - Phase 3 Trial Explanation
2:06 - Difference Between Phase 2 and Phase 3 Trials
3:45 - Trial Size and Enrollment Details
4:46 - Timeline and Market Potential
5:38 - Pericarditis Overview and Phase 2 Results
9:26 - Archer Trials and Myocarditis Program

====================================================================

Looking for better insights on the markets? The Deep Dive Spotlights is providing exclusive industry insights from executives, insiders, technicians, specialists and more.

We're upgrading our Canadian small cap coverage from written to visual, hitting investors with a double dose of market insights to provide a special look into just what's happening in the Canadian public markets.
=================================================================
TheDeepDive.ca Team

Writers: Jordan Lutz & Steve Hyland
Producer: Chriz Rayos
Host: Steve Hyland
Post Production Head: Oveja Rayos

=================================================================



Disclaimer:
Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security. The Deep Dive and its affiliates hold no licenses.